Activin and Inhibin

HHS-0701, a sulfur-triazole exchange (SuTEx) ligand, is a potent tyrosine-reactive prostaglandin reductase 2 (PTGR2) inhibitor. HHS-0701 blocks PTGR2 metabolism of the lipid substrate 15-Keto-PGE2.In VitroHHS-0701 (0.1, 0.25, 0.5, 1, 2.5, 5, 10, 25

HHS-0701, a sulfur-triazole exchange (SuTEx) ligand, is a potent tyrosine-reactive prostaglandin reductase 2 (PTGR2) inhibitor. HHS-0701 blocks PTGR2 metabolism of the lipid substrate 15-Keto-PGE2.In VitroHHS-0701 (0.1, 0.25, 0.5, 1, 2.5, 5, 10, 25

HIF-1α-IN-2 is an effective HIF-1α inhibitor with anticancer potencies ( IC 50 s of 28 nM and 15 nM in MDA-MB-231 and MiaPaCa-2 cells, respectively). HIF-1α-IN-2 suppresses HIF-1α expression by blocking transcription and protein translationIn

HIF-1α-IN-2 is an effective HIF-1α inhibitor with anticancer potencies ( IC 50 s of 28 nM and 15 nM in MDA-MB-231 and MiaPaCa-2 cells, respectively). HIF-1α-IN-2 suppresses HIF-1α expression by blocking transcription and protein translationIn

HIF-1α-IN-2 is an effective HIF-1α inhibitor with anticancer potencies ( IC 50 s of 28 nM and 15 nM in MDA-MB-231 and MiaPaCa-2 cells, respectively). HIF-1α-IN-2 suppresses HIF-1α expression by blocking transcription and protein translationIn

HIF-1α-IN-2 is an effective HIF-1α inhibitor with anticancer potencies ( IC 50 s of 28 nM and 15 nM in MDA-MB-231 and MiaPaCa-2 cells, respectively). HIF-1α-IN-2 suppresses HIF-1α expression by blocking transcription and protein translationIn

HIF-1α-IN-2 is an effective HIF-1α inhibitor with anticancer potencies ( IC 50 s of 28 nM and 15 nM in MDA-MB-231 and MiaPaCa-2 cells, respectively). HIF-1α-IN-2 suppresses HIF-1α expression by blocking transcription and protein translationIn

HIF-2α-IN-3, an allosteric inhibitor of hypoxia inducible factor-2α ( HIF-2α ), exhibits an IC 50 of 0.4 µM and a K D of 1.1 µM. Anticancer agentIn VitroHIF-2α-IN-3 (Compound 1) inhibit HIF-2α-ARNT (also known as HIF-β) heterodimerization by binding

HIF-2α-IN-3, an allosteric inhibitor of hypoxia inducible factor-2α ( HIF-2α ), exhibits an IC 50 of 0.4 µM and a K D of 1.1 µM. Anticancer agentIn VitroHIF-2α-IN-3 (Compound 1) inhibit HIF-2α-ARNT (also known as HIF-β) heterodimerization by binding

HIF-2α-IN-3, an allosteric inhibitor of hypoxia inducible factor-2α ( HIF-2α ), exhibits an IC 50 of 0.4 µM and a K D of 1.1 µM. Anticancer agentIn VitroHIF-2α-IN-3 (Compound 1) inhibit HIF-2α-ARNT (also known as HIF-β) heterodimerization by binding

HIF-2α-IN-3, an allosteric inhibitor of hypoxia inducible factor-2α ( HIF-2α ), exhibits an IC 50 of 0.4 µM and a K D of 1.1 µM. Anticancer agentIn VitroHIF-2α-IN-3 (Compound 1) inhibit HIF-2α-ARNT (also known as HIF-β) heterodimerization by binding

HIF-2α-IN-3, an allosteric inhibitor of hypoxia inducible factor-2α ( HIF-2α ), exhibits an IC 50 of 0.4 µM and a K D of 1.1 µM. Anticancer agentIn VitroHIF-2α-IN-3 (Compound 1) inhibit HIF-2α-ARNT (also known as HIF-β) heterodimerization by binding